Browse by Hotbed/Location
Filter News
Found 703,361 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched. -
Innate Pharma to Participate in Upcoming June 2023 Investor Conferences
5/23/2023
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming conferences.
-
TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension
5/23/2023
TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.
-
Propanc Biopharma Announces Reverse Stock Split - May 23, 2023
5/23/2023
Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s board of directors has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 1,000 pre-split shares.
-
Guardant Health Announces Pricing of Upsized Public Offering of Common Stock - May 23, 2023
5/23/2023
Guardant Health, Inc., a leading precision oncology company, announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions.
-
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5/23/2023
Agile Therapeutics, Inc., a women's healthcare company, announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock, together with accompanying common stock warrants, at a public offering price of $3.9551 per share and accompanying warrants.
-
Spago Nanomedical has Submitted Application to Start Tumorad(R) Clinical Phase I/IIa Study
5/23/2023
Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia.
-
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
5/23/2023
Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA.
-
Immunovia Publishes Interim Report for January-March 2023
5/23/2023
Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60).
-
OMRON Healthcare Celebrates 50 Years of Blood Pressure Monitor History
5/23/2023
OMRON Healthcare Co., Ltd. based in Muko City, Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year.
-
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
5/23/2023
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.
-
BioInvent Strengthens Management with Appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs
5/23/2023
BioInvent International AB announces the appointment of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs.
-
Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
5/23/2023
Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.
-
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
5/23/2023
Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in its Phase I trial of PeptiCRAd-1 in three tumor types.
-
ImmunityBio to Participate in the Jefferies Global Healthcare Conference - May 22, 2023
5/22/2023
ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023, at 10:00 am Eastern Time at the Marriott Marquis, New York.
-
Medigene AG Expands Patent Portfolio for its End-to-End Platform
5/22/2023
Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.
-
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
5/22/2023
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo ® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases.
-
Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June 2023
5/22/2023
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, announced that the Company will participate in the following upcoming investor conferences in May and June.
-
Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023
5/22/2023
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution.